— BMB compound significantly reduced fentanyl intake in an animal model of opioid abuse — — Potential to reduce continued opioid use in humans, a key treatment goal for opioid use disorder — — A brief virtual presentation discussing the findings is scheduled for Monday, March 15 th at 11am ET — VANCOUVER, British Columbia, March 15, 2021 (GLOBE NEWSWIRE) — Bright Minds Biosciences (“Bright Minds,”…


Previous articleNuminus Wellness Inc. Announces $30 Million Bought Deal Public Offering
Next articleDC’s Initiative 81 Becomes Law: Effectively Decriminalizes Entheogenic Plants and Fungi